Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Review

Novel therapeutic strategies targeting HIV integrase

Peter K Quashie12, Richard D Sloan1 and Mark A Wainberg123*

Author Affiliations

1 McGill University AIDS Centre, Lady Davis Institute, Montreal, Canada

2 Division of Experimental Medicine, McGill University, Montreal, Canada

3 Department of Microbiology and Immunology, McGill University, Montreal, Canada

For all author emails, please log on.

BMC Medicine 2012, 10:34  doi:10.1186/1741-7015-10-34

Published: 12 April 2012


Integration of the viral genome into host cell chromatin is a pivotal and unique step in the replication cycle of retroviruses, including HIV. Inhibiting HIV replication by specifically blocking the viral integrase enzyme that mediates this step is an obvious and attractive therapeutic strategy. After concerted efforts, the first viable integrase inhibitors were developed in the early 2000s, ultimately leading to the clinical licensure of the first integrase strand transfer inhibitor, raltegravir. Similarly structured compounds and derivative second generation integrase strand transfer inhibitors, such as elvitegravir and dolutegravir, are now in various stages of clinical development. Furthermore, other mechanisms aimed at the inhibition of viral integration are being explored in numerous preclinical studies, which include inhibition of 3' processing and chromatin targeting. The development of new clinically useful compounds will be aided by the characterization of the retroviral intasome crystal structure. This review considers the history of the clinical development of HIV integrase inhibitors, the development of antiviral drug resistance and the need for new antiviral compounds.

crystal structure; dolutegravir; HIV integrase; mutations; new drugs; raltegravir; resistance